Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
doxorubicin hydrochloride
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(87)
News
Trials
Company:
Generic mfg.
Drug class:
Topoisomerase II inhibitor
Related drugs:
‹
etoposide IV (53)
etoposide oral (33)
pegylated liposomal doxorubicin (31)
epirubicin (29)
daunorubicin (20)
cytarabine/daunorubicin liposomal formulation (19)
idarubicin hydrochloride (16)
mitoxantrone (16)
dactinomycin (8)
teniposide (5)
MM-302 (4)
pixantrone (4)
non-pegylated liposomal doxorubicin (3)
pegylated liposomal doxorubicin (1)
IT-141 (1)
SGN-15 (1)
VLS-211 (1)
zoptarelin doxorubicin (1)
RTA 744 (1)
AVA6000 (0)
amsacrine (0)
amrubicin (0)
mitoxantrone liposomal (0)
H-ferritin–nanocaged doxorubicin (0)
HF158K1 (0)
MNPR-202 (0)
non-pegylated liposomal doxorubicin (0)
vosaroxin (0)
amonafide (0)
SQ3370 (0)
THE001 (0)
lyso-thermosensitive liposomal doxorubicin (0)
tirapazamine (0)
idronoxil (0)
INNO-206 (0)
MNPR-201 (0)
NSC311152 (0)
dexrazoxane (0)
SA033 (0)
doxorubicin liposomal (0)
2X-111 (0)
NP-ACT D (0)
valrubicin (0)
etoposide IV (53)
etoposide oral (33)
pegylated liposomal doxorubicin (31)
epirubicin (29)
daunorubicin (20)
cytarabine/daunorubicin liposomal formulation (19)
idarubicin hydrochloride (16)
mitoxantrone (16)
dactinomycin (8)
teniposide (5)
MM-302 (4)
pixantrone (4)
non-pegylated liposomal doxorubicin (3)
pegylated liposomal doxorubicin (1)
IT-141 (1)
SGN-15 (1)
VLS-211 (1)
zoptarelin doxorubicin (1)
RTA 744 (1)
AVA6000 (0)
amsacrine (0)
amrubicin (0)
mitoxantrone liposomal (0)
H-ferritin–nanocaged doxorubicin (0)
HF158K1 (0)
MNPR-202 (0)
non-pegylated liposomal doxorubicin (0)
vosaroxin (0)
amonafide (0)
SQ3370 (0)
THE001 (0)
lyso-thermosensitive liposomal doxorubicin (0)
tirapazamine (0)
idronoxil (0)
INNO-206 (0)
MNPR-201 (0)
NSC311152 (0)
dexrazoxane (0)
SA033 (0)
doxorubicin liposomal (0)
2X-111 (0)
NP-ACT D (0)
valrubicin (0)
›
Associations
(87)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Breast Cancer
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
No biomarker
Neuroblastoma
No biomarker
Neuroblastoma
doxorubicin hydrochloride
Sensitive: A1 - Approval
doxorubicin hydrochloride
Sensitive
:
A1
doxorubicin hydrochloride
Sensitive: A1 - Approval
doxorubicin hydrochloride
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride
Sensitive
:
A1
docetaxel + doxorubicin hydrochloride
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride
Sensitive
:
A1
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
doxorubicin hydrochloride
Sensitive: A1 - Approval
doxorubicin hydrochloride
Sensitive
:
A1
doxorubicin hydrochloride
Sensitive: A1 - Approval
doxorubicin hydrochloride
Sensitive
:
A1
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
doxorubicin hydrochloride
Sensitive: A1 - Approval
doxorubicin hydrochloride
Sensitive
:
A1
doxorubicin hydrochloride
Sensitive: A1 - Approval
doxorubicin hydrochloride
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Nasopharyngeal Carcinoma
No biomarker
Nasopharyngeal Carcinoma
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
cisplatin + paclitaxel + doxorubicin hydrochloride
Sensitive: A2 - Guideline
cisplatin + paclitaxel + doxorubicin hydrochloride
Sensitive
:
A2
cisplatin + paclitaxel + doxorubicin hydrochloride
Sensitive: A2 - Guideline
cisplatin + paclitaxel + doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
No biomarker
Thyroid Gland Anaplastic Carcinoma
docetaxel + doxorubicin hydrochloride
Sensitive: A2 - Guideline
docetaxel + doxorubicin hydrochloride
Sensitive
:
A2
docetaxel + doxorubicin hydrochloride
Sensitive: A2 - Guideline
docetaxel + doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
No biomarker
Thyroid Gland Anaplastic Carcinoma
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Salivary Gland Cancer
No biomarker
Salivary Gland Cancer
cisplatin + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A2
cisplatin + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
cisplatin + doxorubicin hydrochloride
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride
Sensitive
:
A2
cisplatin + doxorubicin hydrochloride
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Bladder Cancer
No biomarker
Bladder Cancer
cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV
Sensitive
:
A2
cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
Sensitive
:
A2
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate
Sensitive
:
A2
cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide
Sensitive: A2 - Guideline
doxorubicin hydrochloride + ifosfamide
Sensitive
:
A2
doxorubicin hydrochloride + ifosfamide
Sensitive: A2 - Guideline
doxorubicin hydrochloride + ifosfamide
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + ifosfamide + vincristine
Sensitive
:
A2
doxorubicin hydrochloride + ifosfamide + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + ifosfamide + vincristine
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + cyclophosphamide + ifosfamide + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + cyclophosphamide + ifosfamide + vincristine
Sensitive
:
A2
doxorubicin hydrochloride + cyclophosphamide + ifosfamide + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + cyclophosphamide + ifosfamide + vincristine
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
cisplatin + doxorubicin hydrochloride + methotrexate
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + methotrexate
Sensitive
:
A2
cisplatin + doxorubicin hydrochloride + methotrexate
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + methotrexate
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
cisplatin + doxorubicin hydrochloride
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride
Sensitive
:
A2
cisplatin + doxorubicin hydrochloride
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
No biomarker
Adrenal Cortex Carcinoma
cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane
Sensitive
:
A2
cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
No biomarker
Adrenal Cortex Carcinoma
carboplatin + doxorubicin hydrochloride + etoposide IV
Sensitive: A2 - Guideline
carboplatin + doxorubicin hydrochloride + etoposide IV
Sensitive
:
A2
carboplatin + doxorubicin hydrochloride + etoposide IV
Sensitive: A2 - Guideline
carboplatin + doxorubicin hydrochloride + etoposide IV
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
No biomarker
Adrenal Cortex Carcinoma
carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane
Sensitive: A2 - Guideline
carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane
Sensitive
:
A2
carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane
Sensitive: A2 - Guideline
carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
No biomarker
Adrenal Cortex Carcinoma
cisplatin + doxorubicin hydrochloride + etoposide IV
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + etoposide IV
Sensitive
:
A2
cisplatin + doxorubicin hydrochloride + etoposide IV
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + etoposide IV
Sensitive
:
A2
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
doxorubicin hydrochloride + ifosfamide + mesna
Sensitive: A2 - Guideline
doxorubicin hydrochloride + ifosfamide + mesna
Sensitive
:
A2
doxorubicin hydrochloride + ifosfamide + mesna
Sensitive: A2 - Guideline
doxorubicin hydrochloride + ifosfamide + mesna
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login